Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

37 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Molecular Tumor Board of the University Medical Center Groningen (UMCG-MTB): outcome of patients with rare or complex mutational profiles receiving MTB-advised targeted therapy.
de Jager VD, Plomp P, Paats MS, van Helvert S, Elst AT, van den Berg A, Dubbink HJ, van Geffen WH, Zhang L, Hendriks LEL, Hiltermann TJN, Hiddinga BI, Hijmering-Kappelle LBM, Jalving M, Kluiver J, Koopman B, van Kruchten M, van der Logt EMJ, Piet B, van Putten J, Reitsma BH, Rutgers SR, de Vries M, Stigt JA, Groves MR, Timens W, Willems SM, van Kempen LC, Schuuring E, van der Wekken AJ. de Jager VD, et al. Among authors: piet b. ESMO Open. 2024 Nov;9(11):103966. doi: 10.1016/j.esmoop.2024.103966. Epub 2024 Nov 4. ESMO Open. 2024. PMID: 39500140 Free PMC article.
Multicenter Comparison of Molecular Tumor Boards in The Netherlands: Definition, Composition, Methods, and Targeted Therapy Recommendations.
Koopman B, Groen HJM, Ligtenberg MJL, Grünberg K, Monkhorst K, de Langen AJ, Boelens MC, Paats MS, von der Thüsen JH, Dinjens WNM, Solleveld N, van Wezel T, Gelderblom H, Hendriks LE, Speel EM, Theunissen TE, Kroeze LI, Mehra N, Piet B, van der Wekken AJ, Ter Elst A, Timens W, Willems SM, Meijers RWJ, de Leng WWJ, van Lindert ASR, Radonic T, Hashemi SMS, Heideman DAM, Schuuring E, van Kempen LC. Koopman B, et al. Among authors: piet b. Oncologist. 2021 Aug;26(8):e1347-e1358. doi: 10.1002/onco.13580. Epub 2020 Nov 10. Oncologist. 2021. PMID: 33111480 Free PMC article.
A Systematic Evaluation of Cost-Saving Dosing Regimens for Therapeutic Antibodies and Antibody-Drug Conjugates for the Treatment of Lung Cancer.
Ter Heine R, van den Heuvel MM, Piet B, Deenen MJ, van der Wekken AJ, Hendriks LEL, Croes S, van Geel RMJM, Jansman FGA, Boshuizen RC, Franssen EJF, Smit AAJ, Dumoulin DW, Oude Munnink TH, Smit EF, Derijks HJ, van der Leest CH, Hendrikx JJMA, Moes DJAR, de Rouw N. Ter Heine R, et al. Among authors: piet b. Target Oncol. 2023 May;18(3):441-450. doi: 10.1007/s11523-023-00958-6. Epub 2023 Apr 21. Target Oncol. 2023. PMID: 37081309 Free PMC article.
Safety, Efficacy, and Biomarker Analysis of Crizotinib in MET-Mutated Non-Small Cell Lung Cancer-Results from the Drug Rediscovery Protocol.
Verkerk K, van der Wel TJWT, Zeverijn LJ, Geurts BS, Spiekman IAC, de Wit GF, Roepman P, Jansen AML, van der Noort V, Smit EF, Hoeben A, Hendriks LEL, van den Heuvel MM, Piet B, Herder GJM, Hashemi SMS, Gelderblom H, Verheul HMW, Voest EE, de Langen AJ. Verkerk K, et al. Among authors: piet b. Clin Cancer Res. 2024 Dec 2;30(23):5323-5332. doi: 10.1158/1078-0432.CCR-24-1925. Clin Cancer Res. 2024. PMID: 39352721 Clinical Trial.
Proactive monitoring of drug-drug interactions between direct oral anticoagulants and small-molecule inhibitors in patients with non-small cell lung cancer.
Gulikers JL, Otten LS, Hendriks LEL, Winckers K, Henskens Y, Leentjens J, van den Heuvel MM, Ter Heine R, Croes S, Piet B, van Geel RMJM. Gulikers JL, et al. Among authors: piet b. Br J Cancer. 2024 Aug;131(3):481-490. doi: 10.1038/s41416-024-02744-1. Epub 2024 Jun 11. Br J Cancer. 2024. PMID: 38862741 Free PMC article.
Imaging the Rewired Metabolism in Lung Cancer in Relation to Immune Therapy.
van Genugten EAJ, Weijers JAM, Heskamp S, Kneilling M, van den Heuvel MM, Piet B, Bussink J, Hendriks LEL, Aarntzen EHJG. van Genugten EAJ, et al. Among authors: piet b. Front Oncol. 2022 Jan 7;11:786089. doi: 10.3389/fonc.2021.786089. eCollection 2021. Front Oncol. 2022. PMID: 35070990 Free PMC article. Review.
Renal function-based versus standard dosing of pemetrexed: a randomized controlled trial.
de Rouw N, Boosman RJ, Burgers JA, Huitema ADR, Dingemans AC, Derijks HJ, Burger DM, Piet B, Hendriks LEL, Biesma B, Pruis MA, Dumoulin DW, Croes S, Mathijssen RHJ, van den Heuvel MM, Ter Heine R. de Rouw N, et al. Among authors: piet b. Cancer Chemother Pharmacol. 2023 Jan;91(1):33-42. doi: 10.1007/s00280-022-04489-1. Epub 2022 Nov 21. Cancer Chemother Pharmacol. 2023. PMID: 36413252 Free PMC article. Clinical Trial.
Hyperhydration with cisplatin does not influence pemetrexed exposure.
de Rouw N, Derijks HJ, Hilbrands LB, Boosman RJ, Piet B, Koolen SLW, Burgers JA, Dingemans AC, van den Heuvel MM, Hendriks LEL, Aerts JGJV, Croes S, Mathijssen RHJ, Huitema ADR, Burger DM, Biesma B, Ter Heine R. de Rouw N, et al. Among authors: piet b. Br J Clin Pharmacol. 2022 Feb;88(2):871-876. doi: 10.1111/bcp.15031. Epub 2021 Aug 26. Br J Clin Pharmacol. 2022. PMID: 34374116 Free PMC article.
37 results